Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 4:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 51 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Triple IT Therapy Clear all
Terminated Phase 1Phase 2 Interventional Results available

A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

NCT04501614
View directory record Official record
Conditions
Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL), Ph+ Mixed Phenotype Acute Leukemia (MPAL), Philadelphia Chromosome-Like ALL (Ph-like ALL)
Interventions
Ponatinib, Chemotherapy Agents
Drug
Lead sponsor
Takeda
Industry
Eligibility
1 Year to 21 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
13
States / cities
Little Rock, Arkansas • Los Angeles, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 23, 2026, 4:19 PM EDT
Completed Phase 1 Interventional

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

NCT02586987
View directory record Official record
Conditions
Lung Cancer, Melanoma, Head and Neck Carcinoma, Gastroesophageal Cancer, Breast Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer, Biliary Tract Cancer
Interventions
Selumetinib, MEDI4736, Tremelimumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
6
States / cities
Chicago, Illinois • Boston, Massachusetts • Las Vegas, Nevada + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 23, 2026, 4:19 PM EDT
Completed Phase 2 Interventional Results available

Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor

NCT03977467
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Solid Tumor
Interventions
Atezolizumab, Standard of Care Chemotherapy, Tiragolumab
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
7
States / cities
Fort Myers, Florida • St. Petersburg, Florida • Tallahassee, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Oct 23, 2026, 4:19 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Non-Opioid Pain Medications After Intracapsular Adenotonsillectomy

NCT04791761
View directory record Official record
Conditions
Adenotonsillectomy, Post-operative Analgesia, Opioid Use
Interventions
Oxycodone, Ibuprofen, Acetaminophen, Opioid disposal pouch, Opioid disposal education
Drug · Other
Lead sponsor
David Chi, MD
Other
Eligibility
3 Years to 17 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 30, 2024 · Synced Oct 23, 2026, 4:19 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane

NCT05146739
View directory record Official record
Conditions
Acute Myeloid Leukemia Post Cytotoxic Therapy, Myelodysplastic Syndrome Post Cytotoxic Therapy, Myeloid Leukemia Associated With Down Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Mixed Phenotype Acute Leukemia, Refractory Myelodysplastic Syndrome
Interventions
Cytarabine, Fludarabine, Leucovorin, Triple Intrathecal Chemotherapy, Uproleselan
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 17 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 23, 2026, 4:19 PM EDT
Completed Phase 1 Interventional

Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage

NCT03194932
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Venetoclax, Cytarabine, Idarubicin, Intrathecal Triple Therapy, Azacitidine
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 20 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
3
States / cities
Palo Alto, California • Chapel Hill, North Carolina • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Oct 23, 2026, 4:19 PM EDT
Recruiting Phase 2 Interventional

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

NCT06390319
View directory record Official record
Conditions
T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma, Mixed Phenotype Acute Leukemia
Interventions
Dexamethasone, Vincristine, Daunorubicin, Calaspargase pegol, Dasatinib, Venetoclax, Bortezomib, Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine), Cyclophosphamide, Cytarabine, Mercaptopurine, Nelarabine, Methotrexate, Thioguanine
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Year to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
4
States / cities
San Diego, California • Charlotte, North Carolina • Tulsa, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 23, 2026, 4:19 PM EDT
Recruiting Phase 2Phase 3 Interventional

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

NCT03013998
View directory record Official record
Conditions
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Interventions
Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21 Group 1), ficlatuzumab (BAML-16-001-S24), Azacitidine (BAML-16-001-S24), Venetoclax (BAML-16-001-S24), ZE46-0134 (BAML-16-001-S21 Group 2), Bleximenib (BAML-16-001-S25/HO181), Cytarabine (BAML-16-001-S25/HO181), Daunorubicin or Idarubicin (BAML-16-001-S25/HO181), Placebo (BAML-16-001-S25/HO181), Revumenib (BAML-16-001-S26/HO177), Placebo (BAML-16-001-S26/HO177)
Biological · Other · Drug
Lead sponsor
Beat AML, LLC
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2032
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 23, 2026, 4:19 PM EDT
Withdrawn Phase 2 Interventional

Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer

NCT05539365
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
Interventions
Alpha-type-1 Polarized Dendritic Cells, Biopsy, Computed Tomography, Leukapheresis, Pembrolizumab, Quality-of-Life Assessment
Biological · Procedure · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Oct 23, 2026, 4:19 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

NCT03793478
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Quizartinib, Fludarabine, Cytarabine, Intrathecal (IT) triple chemotherapy prophylaxis, Etoposide
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
1 Month to 21 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
11
States / cities
Loma Linda, California • San Francisco, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 23, 2026, 4:19 PM EDT
Terminated Phase 2 Interventional

Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia

NCT03913559
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Inotuzumab ozogamicin, Methotrexate, Hydrocortisone, Cytarabine, Diphenhydramine, Acetaminophen, Methylprednisolone
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
San Diego, California • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 23, 2026, 4:19 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Non-opioids for Analgesia After Adenotonsillectomy in Children

NCT03618823
View directory record Official record
Conditions
Adenotonsillectomy, Post-operative Analgesia, Opioid Use
Interventions
Oxycodone, Ibuprofen, Acetaminophen
Drug
Lead sponsor
David Chi, MD
Other
Eligibility
3 Years to 17 Years
Enrollment
268 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Oct 23, 2026, 4:19 PM EDT
Completed Phase 3 Interventional

Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

NCT00002798
View directory record Official record
Conditions
Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Monoblastic Leukemia (M5a), Childhood Acute Monocytic Leukemia (M5b), Childhood Acute Myeloblastic Leukemia With Maturation (M2), Childhood Acute Myeloblastic Leukemia Without Maturation (M1), Childhood Acute Myelomonocytic Leukemia (M4), Childhood Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Ringed Sideroblasts, Secondary Myelodysplastic Syndromes, Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions
asparaginase, daunorubicin hydrochloride, fludarabine phosphate, therapeutic hydrocortisone, allogeneic bone marrow transplantation, 3-dimensional conformal radiation therapy, filgrastim, cytarabine, idarubicin, dexamethasone, thioguanine, etoposide, methotrexate, cyclophosphamide, aldesleukin, busulfan
Drug · Procedure · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 23, 2026, 4:19 PM EDT
Completed Phase 1 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

NCT03800836
View directory record Official record
Conditions
Breast Cancer
Interventions
Ipatasertib, Paclitaxel, Atezolizumab, Nab-Paclitaxel, AC
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 23, 2026, 4:19 PM EDT
Not listed Phase 2 Interventional

Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma

NCT03961698
View directory record Official record
Conditions
Breast Cancer, Renal Cell Carcinoma
Interventions
IPI-549 (eganelisib), Atezolizumab, nab-paclitaxel, Bevacizumab
Drug
Lead sponsor
Infinity Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
24
States / cities
Chandler, Arizona • Tucson, Arizona • Fullerton, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 23, 2026, 4:19 PM EDT
Not yet recruiting Phase 2 Interventional

RISK-ADAPT Protocol in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

NCT07645326
View directory record Official record
Conditions
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Interventions
Androgen Deprivation Therapy (ADT), Androgen Receptor Pathway Inhibitor (ARPI), Prostate Radiation, Docetaxel
Drug · Radiation
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older · Male only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 23, 2026, 4:19 PM EDT
Not listed Phase 4 Interventional

A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD)

NCT01731301
View directory record Official record
Conditions
Chronic Hepatitis C, End Stage Renal Disease
Interventions
Ribavirin, Peginterferon, Boceprevir
Drug
Lead sponsor
Liver Institute of Virginia
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 22, 2012 · Synced Oct 23, 2026, 4:19 PM EDT
Completed Phase 1 Interventional Results available

Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

NCT02303821
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia (ALL)
Interventions
Carfilzomib, Dexamethasone, Mitoxantrone, PEG-asparaginase, Vincristine, Intrathecal (IT) Methotrexate, Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate), 6-Mercaptopurine, Cyclophosphamide, Cytarabine, Daunorubicin
Drug
Lead sponsor
Amgen
Industry
Eligibility
1 Month to 21 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
22
States / cities
Oakland, California • Orange, California • Aurora, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 23, 2026, 4:19 PM EDT
Active, not recruiting Phase 1 Interventional

A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors

NCT05537740
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
BAY3375968, Pembrolizumab
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Chicago, Illinois • Chapel Hill, North Carolina • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 23, 2026, 4:19 PM EDT
Completed Phase 1 Interventional

Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL

NCT03349281
View directory record Official record
Conditions
Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia
Interventions
Pevonedistat, Vincristine, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, Methotrexate, Hydrocortisone
Drug
Lead sponsor
Julio Barredo, MD
Other
Eligibility
16 Years to 39 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Oct 23, 2026, 4:19 PM EDT
Completed Phase 3 Interventional

Evaluation of Dose-titration of Pramlintide During Initiation of Therapy in Patients Trying to Improve Glucose Control

NCT00042458
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Pramlintide acetate, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
33
States / cities
Mesa, Arizona • Phoenix, Arizona • Concord, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Oct 23, 2026, 4:19 PM EDT
Recruiting Phase 1 Interventional

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

NCT05476770
View directory record Official record
Conditions
Hematologic Malignancy, AML, ALL, BPDCN, MDS, Lymphoblastic Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia, Acute Undifferentiated Leukemia
Interventions
Tagraxofusp, Fludarabine, Cytarabine, Dexamethasone, Vincristine, Azacitidine, Methotrexate, Cytarabine IT, Hydrocortisone
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
29
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2024 · Synced Oct 23, 2026, 4:19 PM EDT
Completed Phase 2 Interventional Results available

A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer

NCT04699630
View directory record Official record
Conditions
Metastatic Breast Cancer, Locally Advanced Breast Cancer
Interventions
U3-1402
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
11
States / cities
Birmingham, Alabama • Springdale, Arkansas • Duarte, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 23, 2026, 4:19 PM EDT
Completed Phase 2 Interventional

An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast Cancer

NCT00580112
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Dexamethasone, Trabectedin
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
21
States / cities
Sedona, Arizona • Denver, Colorado • Torrington, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2014 · Synced Oct 23, 2026, 4:19 PM EDT